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devices. The preference for CPDB by the participants might 
explain the high compliance. Further studies including 
 comparison with biomarkers and transdermal devices are 
needed.  © 2013 S. Karger AG, Basel 
 Introduction 
 Alcohol monitoring to document abstinence is con-
ducted in numerous settings including treatment and re-
covery from alcohol or other substance addiction, court-
ordered abstinence, custody cases in which child visita-
tion is contingent upon parental abstinence, regulatory 
board or professional monitoring programs mandating 
abstinence as a condition of licensure or return to work, 
family or school monitoring of alcohol consumption in 
children, and in medical clinics when alcohol use may 
cause exacerbation of underlying medical problems (e.g. 
diabetes, esophagitis, or liver transplantation). Alcohol 
monitoring in these settings is useful for advocacy, deter-
rence, and early detection of relapse  [1] .
 The value of monitoring alcohol use by measuring its 
presence in blood, breath, or urine is limited since alcohol 
itself remains detectable in the body for a period of hours 
only. Residual biomarkers can, however, provide impor-
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 Abstract 
 Background: Monitoring alcohol use is important in numer-
ous situations. Direct ethanol metabolites, such as ethyl 
glucuronide (EtG), have been shown to be useful tools in de-
tecting alcohol use and documenting abstinence. For very 
frequent or continuous control of abstinence, they lack prac-
ticability. Therefore, devices measuring ethanol itself might 
be of interest. This pilot study aims at elucidating the usabil-
ity and accuracy of the cellular photo digital breathalyzer 
(CPDB) compared to self-reports in a naturalistic setting. 
 Method: 12 social drinkers were included. Subjects used a 
CPDB 4 times daily, kept diaries of alcohol use and submitted 
urine for EtG testing over a period of 5 weeks.  Results: In
total, the 12 subjects reported 84 drinking episodes. 1,609 
breath tests were performed and 55 urine EtG tests were col-
lected. Of 84 drinking episodes, CPDB detected 98.8%. The 
compliance rate for breath testing was 96%. Of the 55 EtG 
tests submitted, 1 (1.8%) was positive.  Conclusions: The data 
suggest that the CPDB device holds promise in detecting 
high, moderate, and low alcohol intake. It seems to have 
 advantages compared to biomarkers and other monitoring 
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tant objective information on more distant drinking status 
that may not be accurately obtained from the patient’s ver-
bal report or clinical examination. They are advantageous 
as compared to traditional biological state markers, such 
as liver enzymes or mean corpuscular volume, since those 
are indirect measures of ethanol intake. Therefore, they are 
limited with regard to the time period for previous drink-
ing and/or are confounded due to age, gender, other in-
gested substance intake and non-alcohol-associated dis-
eases  [2–5] . On this background, direct ethanol metabo-
lites have gained interest during the last two decades.
 Ethyl glucuronide (EtG), a promising marker of alco-
hol intake, is a direct metabolite of alcohol formed as a 
conjugate of alcohol with glucuronic acid in the liver, cat-
alyzed by the enzyme uridine diphosphate glucuronyl-
transferase  [3, 5–7] . EtG is measureable in tissue, blood, 
hair, and, most commonly, in urine  [6] . With an estimat-
ed 5 million or more tests conducted annually in the USA 
[D. Lewis, CEO, US Drug Test Lab, Chicago, 5/2/12, pers. 
commun.] it is the most widely used direct ethanol me-
tabolite. EtG testing has gained widespread use because 
EtG: (1) is detectable in urine (still the most common ma-
trix for testing); (2) can be detected in urine for up to 7 
days; (3) testing is relatively inexpensive, and (4) it is now 
widely available through most reference laboratories.
 Despite its growing popularity, urine EtG (UEtG) test-
ing faces certain limitations. A positive test result can be 
misleading because it can be positive from extraneous ex-
posure to alcohol from any of a myriad of products such 
as food  [8] , mouthwash  [9] , hand-sanitizing gels  [10] , or 
over-the-counter medications. Also, in vitro formation of 
EtG from bacterial action in urine in some settings  [11, 12] 
or from consuming sugar and yeast  [13] has been reported.
 There is no universally agreed upon cutoff that accu-
rately distinguishes between drinking and extraneous ex-
posure. However, based on the fact that exposure studies 
never yielded results >1,000 ng/ml, a differential cutoff 
has been suggested of 1,000 ng/ml or more for EtG to con-
firm drinking  [14] . In addition, a recent revision of the 
SAMHSA advisory suggests that values of between 500 
and 1,000 ng/ml could be from previous drinking as well 
as from recent intense extraneous exposure within 24 h 
or less  [15] .
 Given these limitations, an additional, accurate, con-
venient, and affordable method for monitoring alcohol 
use might be desirable. New devices that appear to hold 
promise have emerged for monitoring alcohol absti-
nence, including transcutaneous alcohol-monitoring de-
vices  [16–18] and, more recently, cellular photo digital 
breathalyzers (CPDB).
 Transcutaneous alcohol-monitoring devices use fuel 
cells to periodically measure alcohol exuded through the 
skin. The results are forwarded daily to a central com-
puter via modem where the readings are analyzed and 
reports are generated. Measurement of alcohol levels in 
this manner have been shown to accurately correlate with 
blood alcohol  [19] . The transcutaneous devices, however, 
also have significant operational drawbacks because they 
must be securely attached to an extremity and must be 
worn continuously. They are therefore cumbersome, in-
trusive, can cause discomfort and may be stigmatizing.
 A new CPDB device that is portable similar to a breath-
alyzer has been introduced. Results are transmitted over 
the cellular network along with a photo. The photo is tak-
en of the user’s face mid-exhalation when the breath al-
cohol is sampled. The facial image is available for visual 
examination to identify the donor along with the breath 
alcohol result immediately on a monitoring website. This 
new device is small and can be carried in a purse or pock-
et and works in conjunction with a smartphone that can 
be programmed to beep when a test is required. The soft-
ware can be set to send an e-mail or text message to the 
monitor to report a positive test or if a test is missed. Ad-
ditionally, if alcohol is detected, a repeat test is automati-
cally requested 15 min later. This is important to elimi-
nate extraneous exposure to alcohol vapor in the atmo-
sphere as a cause for a positive test. Extraneous alcohol 
vapor, which could occur from alcohol hand sanitizer, 
mouthwash, etc., dissipates within a few minutes. These 
devices appear to be simple, affordable, accurate, and re-
flect real-time readings of breath alcohol, as they report 
immediately, and thus may be more sensitive and spe-
cific for alcohol use than other methods.
 This study aims at elucidating the usability and accu-
racy of the CPDB as compared to self-reports in a natu-
ralistic setting. In addition, the results were compared to 
random UEtG testing. The frequencies of use, 4 times dai-
ly for CPDB and weekly testing with EtG, are compared 
because they are practical levels of use in the field for the 
two methods of testing.
 Methods 
 Design 
 This prospective pilot study aims at comparing CPDB, self-re-
ports and UEtG testing for monitoring alcohol use in the same 
subjects over a 5-week period. Subjects were contacted daily by 
phone to encourage compliance, answer questions and to notify 
them when to submit the urine sample. All urine specimens were 
collected between 9 a.m. to 1 p.m. at a designated collection site. 
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Simultaneously, over the same period the subjects were reminded 
to submit CPDB readings 4 times daily: upon arising, after lunch, 
after dinner, and before bedtime. Subjects were asked to keep a 
detailed log of their alcohol use (day, time, type of alcohol, and 
amount) as well as a record of all food, drink, and/or products in 
the environment that might contain alcohol. At the end of the 
study, subjects completed a questionnaire regarding acceptability 
and ease of providing urine and breath samples.
 Subjects 
 Twelve subjects were recruited via a posting on Craig’s List. The 
ad stated, ‘Social drinkers sought to participate in a 5-week alco-
hol-monitoring study. Must be between 21 and 60 with no history 
of alcoholism, addictions, or current pregnancy. Upon completion 
subjects may keep their breathalyzer device, value $650. To par-
ticipate call <phone number>.’ Social drinkers were defined as 
drinking less than 3 times per week. Subjects were screened via 
telephone. Of the first 15 who called, 3 individuals were eliminated 
because they consumed alcohol more than 3 times per week. Of the 
12 selected subjects, 8 were men and 4 women, between 24 and 52 
years of age. All subjects signed informed consent to participate 
and were anonymized. Subjects were allowed to suspend testing 
for 3–8 days because of holidays and vacations and these days were 
added to the end so that all subjects participated in monitoring for 
a total of 35 days.
 Laboratory and CPDB Testing 
 MedTox Diagnostics, Inc., Burlington, N.C., USA, provided 
UEtG testing utilizing the Microgenics immunoassay with reflex 
LC/MS/MS confirmation. The cutoff for the EtG immunoassay 
was 500 ng/ml, and is the most commonly used cutoff. The CPDB 
devices were provided by Soberlink, Inc., Costa Mesa, Calif., 
USA.
 Monitoring Preference 
 Subjects were asked the following questions at the end of the 
study: (1) If you had to choose one method of monitoring over the 
other, would you choose random urine drug testing weekly or 4 
times daily blowing in the Soberlink CPDB device? (2) Please de-
scribe the difference between both methods of monitoring.
 IRB Approval 
 The design of this study as well as all data collection and patient 
protection procedures were reviewed and approved by the full 
membership of a duly constituted Independent Review Board, 
RCRC, Austin, Tex., USA.
 Results 
 The 12 subjects reported 2–22 drinking episodes each 
resulting in a total of 84 drinking episodes. The maximum 
number of drinks per occasion ranged between 2 and 10 
where 1 standard drink was defined as 14 g ethanol ac-
cording to the NIAAA definition  [20] . A total of 1,609 
breath tests were performed and 55 UEtG tests were col-
lected. 
 Of the breath tests, 71 were not collected by 6 subjects 
for various reasons, including ‘forgot to test’ and ‘battery 
was dead’. The compliance rate for successful breath test-
ing was thus 96%. Of the total breath tests, 1,525 (94.8%) 
were negative and 84 (5.2%) were positive. On average, 
positive breath tests were taken approximately 2 h after 
reported drinking episodes (range 8–330 min). Of a total 
of 84 reported drinking episodes, 83 were followed by a 
positive breath test resulting in a sensitivity of 98.8%. In 
1 case, the breath test at 9 p.m. was negative following a 
reported consumption of 3 beers at 6 p.m. There was 1 
false-positive breath test (result 0.007 g/dl) that was un-
Table 1.  Descriptive data of the subjects
Subject Drinking 
episodes
Maximum number
of standard drinks
on one occasion
Number of UEtG
tests/number of
positive UEtG tests
Number of breath 
tests/number of 
positive breath tests
Alcohol levels for positive 
breath tests, g/dl
Minutes from  drink to 
breath test
lowest highest mi n. max.
1 7 3 5/0 140/7 0.007 0.064 59 205
2 2 6 5/0 134/2 0.029 0.105 271 330
3 10 3 5/0 140/10 0.010 0.320 42 255
4 6 5 5/0 140/5 0.006 0.095 47 252
5 4 3 4/0 140/4 0.007 0.088 110 182
6 5 6 5/0 140/5 0.012 0.170 38 66
7 7 4 4/0 122/7 0.015 0.147 15 122
8 22 10 5/1 127/22 0.006 0.257 11 216
9 5 4 5/0 140/5 0.010 0.104 62 139
10 6 3 5/0 120/6 0.014 0.081 24 221
11 2 2 3/0 128/2 0.011 0.013 141 230
12 8 2 4/0 138/8 0.008 0.358 8 308
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 B
er
n 
   
   
   
   
   
   
   
   
   
   
   
   
  
13
0.
92
.9
.5
7 
- 3
/1
2/
20
14
 1
1:
55
:1
4 
AM
 Skipper  /Thon  /DuPont  /Campbell  /
Weinmann  /Wurst  
 
 Eur Addict Res 2014;20:137–142 
DOI: 10.1159/000355834
140
explained. The individual number of breath tests ranged 
from 120 to 140 with positive test levels of between 0.006 
and 0.358 g/dl.
 Of 60 possible UEtG tests, 55 were obtained. Five tests 
were missed by 4 subjects who failed to test for various 
reasons, including ‘forgot to go’ and ‘collection site 
closed’. The compliance rate for successful UEtG testing 
was thus 92%. Of the 55 UEtG tests submitted, 1 (1.8%) 
was positive and 98.2% were negative. The positive test 
was obtained the morning after the subject reported hav-
ing 5 drinks. There were no false-positive UEtG tests (for 
further details, see  table 1 ).
 Regarding the monitoring preference questions, all 
participants preferred the CPDB device. Differences men-
tioned between the two methods of monitoring were the 
following: ‘It’s much easier to take 30 s 4 times per day 
than to drive to a collection site and wait sometimes ½ 
hour to submit a urine sample.’ ‘Much more convenient 
to blow in the Soberlink from home than to go to a collec-
tion site.’ ‘Embarrassing to submit a urine. Easy to blow in 
Soberlink device.’ ‘Much prefer blowing in Soberlink de-
vice.’ ‘No comparison. Prefer blowing.’ ‘Just easier.’ ‘More 
trouble to drive somewhere and wait to give urine sample.’ 
‘1 min per breath test, 30–45 min per urine.’ ‘No compar-
ison.’
 Discussion 
 The major findings of this pilot study employing the 
portable CPDB using data transmission over a cellular 
network along with a photo are: (1) of all reported drink-
ing episodes, 98.8% were detected by the CPDB. (2) The 
compliance rate for successful breath testing was with 
96% extraordinarily high. (3) All participants preferred 
the CPDB over the EtG testing. These findings are of im-
portance since alcohol is one of the most common sub-
stances of abuse.
 UEtG testing has emerged over the past decade and has 
gained widespread use in monitoring; however, it also 
faces certain limitations. These include the fact that only 
a higher dose of ethanol results in detectable UEtG values 
for longer than 24 h: Wojcik and Hawthorne  [21] found 
UEtG to be positive at 24 h in 5 out of 6 cases with doses 
of 0.39–0.85 g ethanol/kg body weight and 0 of 2 with 
doses of 0.19–0.28 g ethanol/kg body weight at a cutoff of 
100 ng/ml. Halter et al.  [11] found 4 out of 13 subjects to 
be UEtG-positive for more than 44 h after an ethanol in-
take of 0.5–0.8 g ethanol/kg body weight. Also in this 
study a low cutoff was chosen with a limit of quantitation 
of 0.45 μmol/l. Since in our study the commonly used cut-
off of 500 ng/ml was used, it cannot be excluded that some 
positives in the range of 100–500 ng/ml were missed. The 
SAMHSA advisory of 2012 on ‘The Role of Biomarkers in 
the Treatment of Alcohol Use Disorders’  [15] states: A 
‘very low’ positive (100–500 ng/ml) may indicate: previ-
ous heavy drinking (1–3 days), previous light drinking 
(12–36 h) or recent ‘extraneous’ exposure. Therefore, to 
monitor for total abstinence, the cutoff of 100 ng/ml has 
been suggested  [14, 15] .
 If some drinking is not detected using the common 
UEtG cutoff, it can encourage subjects to continue to 
drink and presents problems for agencies that rely on the 
tests for detection of drinking and assurance of absti-
nence. Furthermore, if tests are falsely positive, it causes 
false accusations and can lead to unjustified sanctions, 
such as loss of visitation or loss of medical license. There-
fore, a complementary and/or additional accurate and re-
liable method of monitoring alcohol is desirable.
 Our data suggest that the real-time use of a breatha-
lyzer such as a CPDB device could be such a solution. The 
finding that EtG in urine is detectable in social drinkers 
with single drinking episodes only in few cases for more 
than 24 h after doses of 0.5–0.8 g ethanol/kg body weight 
are in line with previous studies  [11, 21] .
 Transdermal alcohol sensors are another method es-
tablished, studied, and validated in the last years as an ef-
fective and feasible method for measuring the transder-
mal alcohol concentration  [16] . One device, the Secure 
Continuous Remote Alcohol Monitoring (SCRAM) 
bracelet, has been evaluated in controlled laboratory en-
vironments and field studies  [18] and furthermore has 
been found to be effective for the reduction of alcohol 
 intake in the context of contingency management  [17] . 
However, embarrassment, experiencing negative atten-
tion, marks on skin, interference with physical activity, 
discomfort  [17] about the bracelet and water accumula-
tion over time  [22] had been reported. Those may limit 
the utility of transdermal devices.
 The CPDB is an unobtrusive, easy-to-use device. As 
the data are transmitted via the cellular network, the par-
ticipants do not have to go to site for a breath test. There-
fore, it is not time-consuming, no staff is directly involved 
and an immediate feedback can be given. Also, partici-
pants may have the opportunity to gain new levels of in-
sight regarding their alcohol consumption. Therefore, 
CPDB cannot only be used as a monitoring instrument 
but also as a therapeutic method, alone or in the context 
of already existing therapeutic approaches such as contin-
gency management.
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 The retail price of the Soberlink device is USD 650 plus 
USD 150 per month for monitoring. The annualized cost 
of monitoring using the CPDB would therefore be USD 
2,450 per person. However, the price remains the same no 
matter how many times the device is used. On the back-
ground of the recent price reduction the annual costs 
would be now USD 2,020. In comparison, usual costs for 
UEtG testing in the USA range between 15 and 30 USD. 
Aiming at a good balance between practicability, reliabil-
ity and security, random UEtG testing on average every 3 
days would result in annual costs of between USD 1,500 
and 3,000. If constant monitoring employing UEtG is de-
sirable, daily testing would be required and result in an-
nual costs of approximately USD 4,500–9,000. However, 
in the case of daily urine testing, practicability is ques-
tioned.
 Limitations 
 The study design aimed at elucidating the usability of 
CPDB. Therefore, the time points for breath tests were 
given and known by the participants. This would in the 
context of monitoring be a severe limitation since sub-
jects can attempt to avoid detection of drinking episodes 
by timing their drinking. To overcome this, random test-
ing is required. It is quite likely that the very good compli-
ance is at least in part due to the daily telephone calls. 
Contacting subjects daily by phone might even be feasible 
in routine settings or also could be done by automated 
text messages. Finally, the fact that participants could 
keep their breathalyzer device at the end of the study 
might have impacted the acceptability outcome.
 Conclusion 
 The data suggest that the CPDB device holds promise 
in detecting not only high but also moderate and low al-
cohol intake. Furthermore, it seems to have advantages as 
compared to biomarker tests and other monitoring de-
vices. The preference for CPDB by the participants might 
explain the high compliance. Further research involving 
a larger number of subjects, longer test periods, different 
subject populations (e.g. individuals in recovery or in 
court-ordered monitoring programs), and comparison 
with biomarkers and transdermal devices are needed.
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